期刊文献+

Biochemical recurrence of prostate cancer: the controversial ~ ecognition and management 被引量:3

Biochemical recurrence of prostate cancer: the controversial ~ ecognition and management
原文传递
导出
摘要 Over the past decade, more and more patients diagnosed as prostate cancer have received radical management attributing to the advent of prostate-specific antigen (PSA) based medical screening. Radical prostatectomy (RP) and radiation therapy (RT) are the most commonly used forms of definitive therapy for clinically localized prostate cancer. However, despite these technique advances, biochemical recurrence (BCR), as determined by subsequent rises in the serum PSA level, is still a challenge that urologists face. Over the past decade, more and more patients diagnosed as prostate cancer have received radical management attributing to the advent of prostate-specific antigen (PSA) based medical screening. Radical prostatectomy (RP) and radiation therapy (RT) are the most commonly used forms of definitive therapy for clinically localized prostate cancer. However, despite these technique advances, biochemical recurrence (BCR), as determined by subsequent rises in the serum PSA level, is still a challenge that urologists face.
机构地区 Department of Urology
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第9期1283-1285,共3页 中华医学杂志(英文版)
  • 相关文献

参考文献28

  • 1Presti JC Jr,Shinohara K,Bacchetti P,Tigrani V,Bhargava V.Positive fraction ofsystematic biopsies predicts risk of relapse after radical prostatectomy.Urology 1998; 52:1079-1084.
  • 2Pound CR,Partin AW,Eisenberger MA,Chan DW,Pearson JD,Walsh PC.Natural history of progression after PSA elevation following radical prostatectomy.JAMA 1999; 281:1591-1597.
  • 3Freedland SJ,Wieder JA,Jack GS,Dorey F,deKernion JB,Aronson WJ.Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.J Urol2002; 168:110-115.
  • 4Moul JW,Connelly RR,Lubeck DP,Bauer J J,Sun L,Flanders SC,et al.Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.J Urol 2001; 166:1322-1327.
  • 5Amling CL,Bergstralh EJ,Blute ML,Slezak JM,Zincke H.Defining prostate specific antigen progression after radical prostatectomy:what is the most appropriate cut point? J Urol 2001; 165:1146-1151.
  • 6Freedland S J,Sutter ME,Dorey F,Aronson WJ.Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy.Prostate-specific antigen.Urology 2003; 61:365-369.
  • 7Aus G,Abbou CC,Bolla M,Heidenreich A,Schmid HP,van Poppel H,et al.EAU guidelines on prostate cancer.Eur Urol 2005; 48:546-551.
  • 8Ferguson RA,Yu H,Kalyvas M,Zammit S,Diamandis EP.Ultrasensitive detection of prostate-specific antigen by a timeresolved immunofluorometric assay and the immulite immunochemiluminescent third-generation assay:potential applications in prostate and breast cancers.Clin Chem 1996;42:675-684.
  • 9American Society for Therapeutic Radiology,Oncology Consensus Panel.Consensus statement:guidelines for PSA following radiation therapy.Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
  • 10Bianco FJ Jr,Scardino PT,Eastham JA.Radical prostatectomy:long-term cancer control and recovery of sexual and urinary function ("trifecta").Urology 2005; 66:83-94.

同被引文献5

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部